Immunotherapy extends survival for gastric cancer patients in China

A clinical trial using Car T-cell therapy for advanced gastric cancer patients shows a 40% increase in survival compared to standard care. This marks a significant advancement in treating solid tumors. The trial involved over 100 patients in China, with those receiving the immunotherapy living an average of 7.9 months, versus 5.5 months for those on standard treatment. The therapy modifies patients' T-cells to target and destroy cancer cells. Experts are hailing the results as groundbreaking, with potential to revolutionize solid tumor treatment. Further studies are underway, including one targeting brain tumors, suggesting broader applications for this innovative approach.